Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12766982 | 1.00 | MAPK1 (0.52) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL10139336 | 1.00 | MAPK1 (0.52) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL11943526 | 0.81 | MAPK1 (0.34) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL6814333 | 0.80 | MAPK1 (0.50) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL18412091 | 0.80 | ACACB (0.44) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL13003758 | 0.79 | POLB (0.49) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL3481587 | 0.79 | ALDH1A1 (0.46) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL17778581 | 0.79 | MAPK1 (0.65) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL16642197 | 0.79 | TDP1 (0.54) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL21510481 | 0.78 | FFAR1 (0.35) | MAPK1TDP1ALDH1A1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-01-21 | — | — | US | disclosed |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-09-05 | — | — | US | disclosed |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-07 | — | — | US | disclosed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-11-30 | — | — | US | disclosed |
| US-20110152518-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-7868013-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7858633-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858633-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7754714-B2 | (1S, 2R)-N4-(2-Aminocarbonylcyclopent-1-yl)-5-fluoro-N2-[4-(4-methylpiperazin-1-yl)-3-methylphenyl]-2,4-pyrimidinediamine, having antiproliferative activity, used to inhibit cellular proliferation and to treat proliferate diseases such as cancers | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | MAPK1 230/4885TDP1 592/4885ALDH1A1 2947/4885 |
| US-20110152518-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | MAPK1 1959/4885TDP1 359/4885ALDH1A1 1807/4885 |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | MAPK1 230/4885TDP1 592/4885ALDH1A1 2947/4885 |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | MAPK1 230/4885TDP1 592/4885ALDH1A1 2947/4885 |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | MAPK1 1959/4885TDP1 359/4885ALDH1A1 1807/4885 |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | MAPK1 1959/4885TDP1 359/4885ALDH1A1 1807/4885 |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | MAPK1 214/4885TDP1 583/4885ALDH1A1 3201/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | MAPK1 62/4885TDP1 1811/4885ALDH1A1 4480/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | MAPK1 192/4885TDP1 1066/4885ALDH1A1 4690/4885 |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | MAPK1 230/4885TDP1 592/4885ALDH1A1 2947/4885 |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | MAPK1 230/4885TDP1 592/4885ALDH1A1 2947/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | MAPK1 230/4885TDP1 592/4885ALDH1A1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.